ASND News

Edge Therapeutics, which is developing a sustained-release therapy for ruptured brain aneurysms, announced terms for its IPO on Monday. The Berkeley Heights, NJ-based company plans to raise $85 million by offering 5.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Edge Therapeutics would command a fully diluted market value of $435 million...read more

Ten IPOs raised $1.2 billion in a week dominated by eight health care IPOs and distinguished by two deals that gained over 100% on the first day - fast casual burger chain Shake Shack and gene therapy biotech Spark Therapeutics. There were more health care IPOs this past week than any week in 2014, a year that had over 100 from the sector. With 14 IPOs to date, January 2015 fell...read more

Ascendis Pharma, which is developing long-acting treatments for growth hormone deficiency, raised $108 million by offering 6 million shares (vs. 5 million originally planned) at $18, the high end of the $16 to $18 range. Ascendis Pharma will list on the NASDAQ under the symbol ASND. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as joint bookrunners on the...read more

Twelve IPOs are set to raise $1 billion in the upcoming week, which would make it the busiest five-day stretch for IPOs since the week of July 28. Shake Shack's IPO offers investors a chance to own a fast-growing fast casual concept based in New York. Ten of the twelve deals are health care, as last year's most popular sector continues to outperform. Assuming they all price, there...read more